1.Adegoke, OAJ, Abdullahi, A & Tavajohi-Fini, P (2012) mTORC1 and the regulation of skeletal muscle anabolism and mass. Appl Physiol Nutr Metab 37, 395–406.
2.Egerman, MA & Glass, DJ (2014) Signaling pathways controlling skeletal muscle mass. Crit Rev Biochem Mol Biol 49, 59–68.
3.Yecies, JL & Manning, BD (2011) mTOR links oncogenic signaling to tumor cell metabolism. J Mol Med 89, 221–228.
4.Barazzoni, R, Short, KR, Asmann, Y et al. (2012) Insulin fails to enhance mTOR phosphorylation, mitochondrial protein synthesis, and ATP production in human skeletal muscle without amino acid replacement. Am J Physiol Endocrinol Metab 303, E1117–E1125.
5.Guertin, DA & Sabatini, DM (2007) Defining the role of mTOR in cancer. Cancer Cell 12, 9–22.
6.Rittig, N, Bach, E, Thomsen, HH et al. (2016) Amino acid supplementation is anabolic during the acute phase of endotoxin-induced inflammation: a human randomized crossover trial. Clin Nutr 35, 322–330.
7.Sandri, M (2016) Protein breakdown in cancer cachexia. Semin Cell Dev Biol 54, 11–19.
8.Lecker, SH, Jagoe, RT, Gilbert, A et al. (2004) Multiple types of skeletal muscle atrophy involve a common program of changes in gene expression. FASEB J 18, 39–51.
9.Baracos, VE, Martin, L, Korc, M et al. (2018) Cancer-associated cachexia. Nat Rev Dis Primers 4, 1–18.
10.Braun, TP, Zhu, X, Szumowski, M et al. (2011) Central nervous system inflammation induces muscle atrophy via activation of the hypothalamic–pituitary–adrenal axis. J Exp Med 208, 2449–2463.
11.Tashjian, AH (1978) Role of prostaglandins in the production of hypercalcemia by tumors. Cancer Res 38, 4138–4141.
12.Strelkov, AB, Fields, AL & Baracos, VE (1989) Effects of systemic inhibition of prostaglandin production on protein metabolism in tumor-bearing rats. Am J Physiol 257, C261–C269.
13.Bodine, SC & Baehr, LM (2014) Skeletal muscle atrophy and the E3 ubiquitin ligases MuRF1 and MAFbx/atrogin-1. AJP Endocrinol Metab 307, E469–E484.
14.Yuan, L, Han, J, Meng, Q et al. (2015) Muscle-specific E3 ubiquitin ligases are involved in muscle atrophy of cancer cachexia: an in vitro and in vivo study. Oncol Rep 33, 2261–2268.
15.Loomans, HA, Andl, CD, Andl, CD et al. (2014) Intertwining of activin a and TGFβ signaling: dual roles in cancer progression and cancer cell invasion. Cancers (Basel) 7, 70–91.
16.Cohen, S, Nathan, JA & Goldberg, AL (2015) Muscle wasting in disease: molecular mechanisms and promising therapies. Nat Rev Drug Discov 14, 58–74.
17.Chen, JL, Walton, KL, Qian, H et al. (2016) Differential effects of IL6 and activin A in the development of cancer-associated cachexia. Cancer Res 76, 5372–5382.
18.Lerner, L, Tao, J, Liu, Q et al. (2016) MAP3K11/GDF15 axis is a critical driver of cancer cachexia. J Cachexia Sarcopenia Muscle 7, 467–482.
19.Loumaye, A, De Barsy, M, Nachit, M et al. (2015) Role of activin A and myostatin in human cancer cachexia. J Clin Endocrinol Metab 100, 2030–2038.
20.Togashi, Y, Kogita, A, Sakamoto, H et al. (2015) Activin signal promotes cancer progression and is involved in cachexia in a subset of pancreatic cancer. Cancer Lett 356, 819–827.
21.Awad, S, Tan, BH, Cui, H et al. (2012) Marked changes in body composition following neoadjuvant chemotherapy for oesophagogastric cancer. Clin Nutr 31, 74–77.
22.Kubrak, C, Olson, K, Jha, N et al. (2012) Clinical determinants of weight loss in patients receiving radiation and chemoirradiation for head and neck cancer: a prospective longitudinal view. Head Neck 35, 695–703.
23.Silver, HJ, Dietrich, MS & Murphy, BA (2007) Changes in body mass, energy balance, physical function, and inflammatory state in patients with locally advanced head and neck cancer treated with concurrent chemoradiation after low-dose induction chemotherapy. Head Neck 29, 893–900.
24.Cooper, AB, Slack, R, Fogelman, D et al. (2015) Characterization of anthropometric changes that occur during neoadjuvant therapy for potentially resectable pancreatic cancer. Ann Surg Oncol 22, 2416–2423.
25.Sorensen, JC, Cheregi, BD, Timpani, CA et al. (2016) Mitochondria: inadvertent targets in chemotherapy-induced skeletal muscle toxicity and wasting?. Cancer Chemother Pharmacol 78, 673–683.
26.Antoun, S, Birdsell, L, Sawyer, MB et al. (2010) Association of skeletal muscle wasting with treatment with sorafenib in patients with advanced renal cell carcinoma: results from a placebo controlled study. J Clin Oncol 28, 1054–1060.
27.Sorensen, JC, Petersen, AC, Timpani, CA et al. (2017) BGP-15 protects against oxaliplatin induced skeletal myopathy and mitochondrial reactive oxygen species production in mice. Front Pharmacol 8, 1–19.
28.Sirago, G, Conte, E, Fracasso, F et al. (2017) Growth hormone secretagogues hexarelin and JMV2894 protect skeletal muscle from mitochondrial damages in a rat model of cisplatin induced cachexia. Sci Rep 7, 1–14.
29.Nissinen, TA, Degerman, J, Räsänen, M et al. (2016) Systemic blockade of ACVR2B ligands prevents chemotherapy-induced muscle wasting by restoring muscle protein synthesis without affecting oxidative capacity or atrogenes. Sci Rep 6, 1–16.
30.Conte, E, Camerino, GM, Mele, A et al. (2017) Growth hormone secretagogues prevent dysregulation of skeletal muscle calcium homeostasis in a rat model of cisplatin-induced cachexia. J Cachexia Sarcopenia Muscle 8, 386–404.
31.Chen, M, Hsu, W, Hwang, P et al. (2016) Combined administration of fucoidan ameliorates tumor and chemotherapy-induced skeletal muscle atrophy in bladder cancer-bearing mice. Oncotarget 7, 51608–51618.
32.Ratnayake, WMN & Galli, C (2009) Fat and fatty acid terminology, methods of analysis and fat digestion and metabolism: a background review paper. Ann Nutr Metab 55, 8–43.
33.Luo, L & Liu, M (2016) Adipose tissue in control of metabolism. J Endocrinol 231, R77–R99.
34.Voss, TS, Vendelbo, MH, Kampmann, U et al. (2017) Effects of insulin-induced hypoglycaemia on lipolysis rate, lipid oxidation and adipose tissue signalling in human volunteers: a randomised clinical study. Diabetologia 60, 143–152.
35.Agustsson, T, Rydén, M, Hoffstedt, J et al. (2007) Mechanism of increased lipolysis in cancer cachexia. Cancer Res 67, 5531–5537.
36.Garcia, JM, Scherer, T, Chen, JA et al. (2013) Inhibition of cisplatin-induced lipid catabolism and weight loss by ghrelin in male mice. Endocrinology 154, 3118–3129.
37.Biondo, LA, Lima, EA, Souza, CO et al. (2016) Impact of doxorubicin treatment on the physiological functions of white adipose tissue. PLoS ONE 11, 1–14.
38.Klose, R, Krzywinska, E, Castells, M et al. (2016) Targeting VEGF-A in myeloid cells enhances natural killer cell responses to chemotherapy and ameliorates cachexia. Nat Commun 7, 1–14.
39.Shellock, FG, Riedinger, MS & Fishbein, MC (1986) Brown adipose tissue in cancer patients: possible cause of cancer-induced cachexia. J Cancer Res Clin Oncol 111, 82–85.
40.Petruzzelli, M, Schweiger, M, Schreiber, R et al. (2014) A switch from white to brown fat increases energy expenditure in cancer-associated cachexia. Cell Metab 20, 433–447.
41.Kir, S, White, JP, Kleiner, S et al. (2014) Tumor-derived PTHrP triggers adipose tissue browning and cancer cachexia. Nature 513, 100–104.
42.Tsoli, M, Moore, M, Burg, D et al. (2012) Activation of thermogenesis in brown adipose tissue and dysregulated lipid metabolism associated with cancer cachexia in mice. Cancer Res 72, 4372–4382.
43.Han, J, Meng, Q, Shen, L et al. (2018) Interleukin-6 induces fat loss in cancer cachexia by promoting white adipose tissue lipolysis and browning. Lipids Health Dis 17, 14.
44.Xue, Y, Yu, F, Yan, D et al. (2015) Zinc-α−2-glycoprotein: a candidate biomarker for colon cancer diagnosis in Chinese population. Int J Mol Sci 16, 691–703.
45.Cabassi, A & Tedeschi, S (2013) Zinc-α2-glycoprotein as a marker of fat catabolism in humans. Curr Opin Clin Nutr Metab Care 16, 267–271.
46.Sagar, G, Sah, RP, Javeed, N et al. (2016) Pathogenesis of pancreatic cancer exosome-induced lipolysis in adipose tissue. Gut 65, 1165–1174.
47.Sidler, B, Alpert, L, Henderson, JE et al. (1996) Amplification of the parathyroid hormone-related peptide gene in a colonic carcinoma. J Clin Endocrinol Metab 81, 2841–2847.
48.Kong, F, Lei, L, Du, Y et al. (2017) Exosomal adrenomedullin derived from cancer-associated fibroblasts promotes lipolysis in adipose tissue. Gut 1-2-2017–315778.
49.Bourdel-Marchasson, I, Blanc-Bisson, C, Doussau, A et al. (2014) Nutritional advice in older patients at risk of malnutrition during treatment for chemotherapy: a two-year randomized controlled trial. PLoS ONE 9, 1–8.
50.Breitkreutz, R, Tesdal, K, Jentschura, D et al. (2005) Effects of a high-fat diet on body composition in cancer patients receiving chemotherapy: a randomized controlled study. Wien Klin Wochenschr 117, 685–692.
51.Ovesen, L, Allingstrup, L, Hannibal, J et al. (1993) Effect of dietary counseling on food intake, body weight, response rate, survival, and quality of life in cancer patients undergoing chemotherapy: a prospective, randomized study. J Clin Oncol 11, 2043–2049.
52.Macdonald, AJ, Johns, N, Stephens, N et al. (2015) Habitual myofibrillar protein synthesis is normal in patients with upper GI cancer cachexia. Clin Cancer Res 21, 1734–1741.
53.Temel, JS, Abernethy, AP, Currow, DC et al. (2016) Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): results from two randomised, doubleblind, phase 3 trials. Lancet Oncol 17, 519–531.
54.Acharyya, S, Butchbach, MER, Sahenk, Z et al. (2005) Dystrophin glycoprotein complex dysfunction: a regulatory link between muscular dystrophy and cancer cachexia. Cancer Cell 8, 421–432.
55.Deutz, NEP, Safar, A, Schutzler, S et al. (2011) Muscle protein synthesis in cancer patients can be stimulated with a specially formulated medical food. Clin Nutr 30, 759–768.
56.Winter, A, MacAdams, J & Chevalier, S (2012) Normal protein anabolic response to hyperaminoacidemia in insulin-resistant patients with lung cancer cachexia. Clin Nutr 31, 765–773.
57.Baracos, VE (2015) Skeletal muscle anabolism in patients with advanced cancer. Lancet Oncol 16, 13–14.
58.Arends, J, Bachmann, P, Baracos, V et al. (2017) ESPEN guidelines on nutrition in cancer patients. Clin Nutr 36, 11–48.
59.Chanet, A, Verlaan, S, Salles, J et al. (2017) Supplementing breakfast with a vitamin D and leucine-enriched whey protein medical nutrition drink enhances postprandial muscle protein synthesis and muscle mass in healthy older men. J Nutr 147, 2262–2271.
60.Engelen, MPKJ, van der Meij, BS & Deutz, NEP (2016) Protein anabolic resistance in cancer: does it really exist? Curr Opin Clin Nutr Metab Care 19, 39–47.
61.Mitchell, CJ, Milan, AM, Mitchell, SM et al. (2017) The effects of dietary protein intake on appendicular lean mass and muscle function in elderly men: a 10-wk randomized controlled trial. Am J Clin Nutr 106, 1375–1383.
62.Pappalardo, G, Almeida, A & Ravasco, P (2015) Eicosapentaenoic acid in cancer improves body composition and modulates metabolism. Nutrition 31, 549–555.
63.Giorgio, F, Girolamo, D, Situlin, R et al. (2014) Omega-3 fatty acids and protein metabolism: enhancement of anabolic interventions for sarcopenia. Curr Opin Clin Nutr Metab Care 17, 145–150.
64.Schiessel, DL, Yamazaki, RK, Kryczyk, M et al. (2016) Does oil rich in alpha-linolenic fatty acid cause the same immune modulation as fish oil in walker 256 tumor-bearing rats? Nutr Cancer 68, 1369–1380.
65.Liu, Y, Chen, F, Odle, J et al. (2013) Fish oil increases muscle protein mass and modulates Akt/FOXO, TLR4, and NOD signaling in weanling piglets after lipopolysaccharide challenge. J Nutr 143, 1331–1339.
66.Smith, GI, Atherton, P, Reed, DN et al. (2011) Dietary omega-3 fatty acid supplementation increases the rate of muscle protein synthesis in older adults: a randomized controlled trial. Am J Clin Nutr 93, 402–412.